Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Kim D, Chung H, Abed M, Ma J, Molden N, Shim C, Rajendran D, Yen J, Jeong J, Levy A, Yaniz-Galende E, Blanc-Durand F, Desauw C, Follana P, Bonichon-Lamichhane N, Oudard S, D'Hondt V, Gavoille C, Jandial DD, Meric-Bernstam F, Liu JF, Simpkins F, Randall LM, Leary A, Lackner MR, Harismendy O

Open source

DOI: 10.1038/s41698-026-01519-6
Published: 2026 May 30
Container: NPJ precision oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41698-026-01519-6,
  title = {Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.},
  author = {Kim D and Chung H and Abed M and Ma J and Molden N and Shim C and Rajendran D and Yen J and Jeong J and Levy A and Yaniz-Galende E and Blanc-Durand F and Desauw C and Follana P and Bonichon-Lamichhane N and Oudard S and D'Hondt V and Gavoille C and Jandial DD and Meric-Bernstam F and Liu JF and Simpkins F and Randall LM and Leary A and Lackner MR and Harismendy O},
  year = {2026},
  journal = {NPJ precision oncology},
  doi = {10.1038/s41698-026-01519-6},
  url = {https://doi.org/10.1038/s41698-026-01519-6}
}

RIS

TY  - JOUR
TI  - Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.
AU  - Kim D
AU  - Chung H
AU  - Abed M
AU  - Ma J
AU  - Molden N
AU  - Shim C
AU  - Rajendran D
AU  - Yen J
AU  - Jeong J
AU  - Levy A
AU  - Yaniz-Galende E
AU  - Blanc-Durand F
AU  - Desauw C
AU  - Follana P
AU  - Bonichon-Lamichhane N
AU  - Oudard S
AU  - D'Hondt V
AU  - Gavoille C
AU  - Jandial DD
AU  - Meric-Bernstam F
AU  - Liu JF
AU  - Simpkins F
AU  - Randall LM
AU  - Leary A
AU  - Lackner MR
AU  - Harismendy O
PY  - 2026
JO  - NPJ precision oncology
DO  - 10.1038/s41698-026-01519-6
UR  - https://doi.org/10.1038/s41698-026-01519-6
ER  -

APA

D, K., H, C., M, A., J, M., N, M., C, S., D, R., J, Y., J, J., A, L., E, Y., F, B., C, D., P, F., N, B., S, O., V, D., C, G., DD, J., F, M., JF, L., F, S., LM, R., A, L., MR, L., & O, H. (2026). Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.. NPJ precision oncology. https://doi.org/10.1038/s41698-026-01519-6

Source records

pubmed · retrieved 2026-09-25T21:09:23.502Z